GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating reiterated by equities research analysts at Citigroup Inc. in a research note issued on Friday. They presently have a GBX 1,700 ($21.96) price target on the stock. Citigroup Inc.’s price target would indicate a potential upside of 13.79% from the company’s previous close.

GSK has been the subject of a number of other research reports. Berenberg Bank raised GlaxoSmithKline plc from a “hold” rating to a “buy” rating and lifted their target price for the stock from GBX 1,850 ($23.89) to GBX 1,885 ($24.34) in a report on Friday, May 26th. Liberum Capital restated a “buy” rating and issued a GBX 1,900 ($24.54) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 27th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.54) price target on GlaxoSmithKline plc and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Jefferies Group LLC raised their price target on GlaxoSmithKline plc from GBX 1,800 ($23.25) to GBX 1,900 ($24.54) and gave the stock a “buy” rating in a research note on Friday, June 16th. Finally, BNP Paribas set a GBX 1,620 ($20.92) price target on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the stock. GlaxoSmithKline plc has an average rating of “Hold” and a consensus target price of GBX 1,714.48 ($22.14).

GlaxoSmithKline plc (LON:GSK) opened at 1494.00 on Friday. GlaxoSmithKline plc has a 12 month low of GBX 1,446.50 and a 12 month high of GBX 1,745.56. The stock’s market cap is GBX 73.03 billion. The stock’s 50 day moving average price is GBX 1,521.96 and its 200-day moving average price is GBX 1,615.99.

GlaxoSmithKline plc (LON:GSK) last posted its earnings results on Wednesday, July 26th. The company reported $0.52 EPS for the quarter, missing the Zacks’ consensus estimate of $26.23 by $25.71. GlaxoSmithKline plc had a return on equity of 295.67% and a net margin of 16.56%. Analysts anticipate that GlaxoSmithKline plc will post $110.99 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Citigroup Inc. Reiterates Neutral Rating for GlaxoSmithKline plc (GSK)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at

In other GlaxoSmithKline plc news, insider Victoria Whyte sold 4,820 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of GBX 1,693 ($21.86), for a total transaction of £81,602.60 ($105,388.87). Also, insider Patrick Vallance purchased 861 shares of the firm’s stock in a transaction on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($20.90) per share, for a total transaction of £13,930.98 ($17,991.71). Over the last three months, insiders have acquired 3,144 shares of company stock worth $5,043,015.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.